Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 60.6%

Gross margin was 60.6% in Q1 FY2026, up 5.8 pp from a year earlier. On a trailing-twelve-month basis it was 60.7%, up 3.0 pp year over year. Over 3 fiscal years it widened by 14.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
60.6%-1.9 pp QoQ
Last fiscal yearDec 2025
59.3%-0.4 pp YoY
LTMMar 2026
60.7%+3.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.8 pp——
1 year-0.4 pp——
3 years+14.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
59.3%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 gross margin of 60.7% is the 2nd highest of the 3 companies compared; the peer median is 67.1%.
  • Its year-over-year change of +3.0 pp is the highest of 3, against a peer median of -7.6 pp.
  • Over three fiscal years its change of +14.2 pp compares with a peer median of -6.3 pp.
COLL Competitors Peer median
Gross Margin for COLL and competitors
Company Period LTM level YoY 3-year change
PCRXPacira BioSciences, Inc.LTM Mar 202679.3% +1.7 pp+9.3 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
SCLXScilex Holding CompanyLTM Mar 202655.0% -17.0 pp-21.9 pp
LTGOLatigo Biotherapeutics Inc.—— ——
Peer median (excluding COLL) 67.1%-7.6 pp-6.3 pp

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue276.87M463.93M566.77M631.45M780.57M
Cost of Revenue126.25M254.45M240.6M254.11M317.31M
Gross Profit150.62M209.49M326.17M377.34M463.26M
Gross Margin54.4%45.2%57.5%59.8%59.3%
Research & Development9.45M3.98M000
Selling, General & Admin118.96M172.19M159.21M182.98M276.17M
Operating Expenses132.99M176.17M159.21M207.45M276.17M
Depreciation & Amortization68.92M138.94M149.26M169.16M226.07M
EBITDA86.56M173.31M308.33M341.7M401.01M
EBITDA Margin31.3%37.4%54.4%54.1%51.4%
Operating Income17.63M33.32M166.96M169.9M187.08M
Operating Margin6.4%7.2%29.5%26.9%24.0%
Interest Income12K1.05M15.62M13.98M11.29M
Interest Expense21.01M63.21M83.34M73.97M82.31M
Other Income / Expenses(21M)(62.17M)(91.23M)(71.33M)(94.47M)
Income Before Tax(3.37M)(28.85M)75.73M98.57M92.62M
Pre-Tax Margin-1.2%-6.2%13.4%15.6%11.9%
Income Tax Expense(74.89M)(3.85M)27.58M29.38M29.75M
Net Income71.52M(25M)48.16M69.19M62.87M
Net Margin25.8%-5.4%8.5%11.0%8.1%
EPS (Basic)2.05(0.74)1.602.141.98
EPS (Diluted)1.86(0.74)1.291.861.73
Weighted Avg Shares34.94M33.83M33.74M32.27M31.71M
Weighted Avg Shares (Diluted)41.05M33.83M41.79M40.42M39.7M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.